Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.

Banerjee S, Zvelebil M, Furet P, Mueller-Vieira U, Evans DB, Dowsett M, Martin LA.

Cancer Res. 2009 Jun 1;69(11):4716-23. doi: 10.1158/0008-5472.CAN-08-4711. Epub 2009 May 12.

2.

Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.

Banerjee S, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, Martin LA.

Clin Cancer Res. 2010 Aug 15;16(16):4178-87. doi: 10.1158/1078-0432.CCR-10-0456. Epub 2010 Aug 3.

3.
4.

Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.

Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G.

Mol Cancer Ther. 2009 Jan;8(1):55-63. doi: 10.1158/1535-7163.MCT-08-0679.

5.
6.

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.

Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.

PMID:
16172907
7.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

8.

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.

Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP.

Semin Oncol. 2003 Jun;30(3 Suppl 6):32-8. Review.

PMID:
12802793
9.

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.

Cancer Res. 2002 Sep 1;62(17):5019-26.

11.
12.

Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.

Barbarroja N, Torres LA, Luque MJ, Carretero RM, Valverde-Estepa A, Lopez-Sanchez LM, Rodriguez-Ariza A, Velasco F, Torres A, López-Pedrera C.

Exp Hematol. 2009 Jun;37(6):679-91. doi: 10.1016/j.exphem.2009.03.001.

PMID:
19463770
13.

Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.

Hos D, Bock F, Dietrich T, Onderka J, Kruse FE, Thierauch KH, Cursiefen C.

Invest Ophthalmol Vis Sci. 2008 May;49(5):1836-42. doi: 10.1167/iovs.07-1314.

PMID:
18436817
14.

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.

Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP.

J Clin Oncol. 2005 Jun 20;23(18):4162-71. Epub 2005 May 2.

PMID:
15867205
15.

PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.

Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC.

Neurosurgery. 2004 Aug;55(2):426-32; discussion 432.

PMID:
15271251
16.

Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.

Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, Christian S, Boos A, Hess-Stumpp H, Foekens JA, Setyono-Han B, Wood J, Hynes NE.

Cancer Res. 2008 Mar 1;68(5):1581-92. doi: 10.1158/0008-5472.CAN-06-4685.

17.

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ.

Leukemia. 2006 Jun;20(6):952-7.

PMID:
16617323
18.
19.

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marmé D.

Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.

PMID:
15705616
20.

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C.

Eur J Cancer. 2005 Jun;41(9):1291-9.

PMID:
15939265

Supplemental Content

Support Center